A. Maroccia

Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients

Enrica Antonia Martino, Salvatore Palmieri, Mónica Galli, Daniele Derudas et autres

Background Daratumumab-refractory multiple myeloma (Dara-R MM) presents a significant treatment challenge. This study aimed to evaluate the efficacy and survival outcomes of elotuzumab, pomalidomide, and dexamethasone (EloPd) in a large, real-world cohort of patients with Dara-R MM, with particular focus on progression-free …

it (code pays fourni par la source)

P27 HIGH DOSE CYCLOPHOSPHAMIDE AS MOBILIZATION REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA: SAFETY AND EFFICACY IN AN OUTPATIENT SETTING. SINGLE CENTER EXPERIENCE

Luca Massarotti, A. Branca, Laura Pavan, A. Maroccia et autres

Background and aim of the study: High-dose chemotherapy followed by autologous stem-cells transplantation (ASCT) is the standard treatment approach in eligible newly diagnosed multiple myeloma (MM) patients. The use of Daratumumab in frontline therapy seems to affect stem cell mobilization and engraftment …

it, cn (code pays fourni par la source)

P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS

G. Barilà, Anna Pascarella, Concetta Conticello, Roberto Mina et autres

According to 2021 ESMO guidelines, treatment of newly diagnosed (ND) transplant eligible (TE) Multiple Myeloma (MM) patients is settled by an induction phase followed by single or tandem autologous stem cell transplantation (ASCT) and Lenalidomide (Len) maintenance. Before the recent approval of …

it (code pays fourni par la source)

Latissimus dorsi breast reconstruction with or without implants: A comparison between outcome and patient satisfaction

Sara Leuzzi, Alessio Stivala, J.B. Shaff, A. Maroccia et autres

fr, it (code pays fourni par la source)